Evidence map›Paper›PMID 41866813›Full record

ArticleChemMedChem2026

Strategic Key Performance Indicators for AI in Lead Optimization.

Theodor Theis, Stefanie Flohr, Hayley Binch, Werngard Czechtizky, Ewa Chudyk, Markus Klein, Mireille Krier, Franz von Nussbaum

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Theodor TheisMedicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riß, Germany.ORCID https://orcid.org/0009-0002-2551-7439
Stefanie FlohrNovartis Institute of Biomedical Research, Novartis AG, Basel, Switzerland.ORCID https://orcid.org/0000-0003-3317-5811
Hayley BinchRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Werngard CzechtizkyMedicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, Mölndal, Sweden.
Ewa ChudykDigital Life Science Chemistry, Nuvisan ICB GmbH, Berlin, Germany.
Markus KleinMerck KGaA, Darmstadt, Germany.
Mireille KrierApplication Science, OpenEye, Cadence Molecular Sciences, Cologne, Germany.
Franz von NussbaumDigital Drug Discovery & Development, Nuvisan ICB GmbH, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With increasing cost and failure rates in the pharmaceutical R&D process not fundamentally improving over the last decade, pressure remains high to increase the probability of success to improve the effectiveness of pharmaceutical R&D. The broad introduction of AI into the R&D landscape over the last years holds the promise to lift pharmaceutical R&D out of its productivity problem, as preliminary analyses suggest that "AI-native" companies may be outpacing traditional peers. However, harnessing this potential requires moving beyond measuring technical model performance (e.g., predictive accuracy) to measuring strategic impact. In this perspective, members of the EFMC

Indexed as

Artificial IntelligenceDrug DiscoveryComputer-Aided DesignDrug DesignHumansartificial intelligencecomputational chemistrykey performance indicators

Identifiers

PMID41866813
PMCPMC13006745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.